New hope for liver transplant patients: drug may stop deadly fungal infections
NCT ID NCT06774144
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This study tests a new antifungal drug called rezafungin to prevent serious fungal infections in liver transplant patients at high risk. About 385 adults receiving a liver transplant will get the drug, and their infection rates will be compared to similar patients from the past two years. The goal is to see if rezafungin can safely reduce infections and improve outcomes after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UPMC Presbyterian
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.